Treatment for Inflammation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Inflammation+4 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial looked at whether the results of two point-of-care tests for blood clotting and inflammation were comparable to those of reference laboratory tests.

Eligible Conditions
  • Inflammation
  • Infection
  • Embolism and Thrombosis

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 months

2 months
Assessment of sample matrix comparison

Trial Safety

Trial Design

0 Treatment Group

200 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 months

Who is running the clinical trial?

LumiraDx UK LimitedLead Sponsor
13 Previous Clinical Trials
31,501 Total Patients Enrolled
2 Trials studying Inflammation
20,079 Patients Enrolled for Inflammation
William SimonPrincipal InvestigatorNew Medical Healthcare
2 Previous Clinical Trials
2,200 Total Patients Enrolled
Matthew MorganPrincipal InvestigatorCentura Health Physician Group
2 Previous Clinical Trials
2,200 Total Patients Enrolled
Anita ScribnerPrincipal InvestigatorDiagnostic Clinic of Longview
Judith KirsteinPrincipal InvestigatorRancho Paseo Medical Group

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.